Market demand has spurred the development of the industry. Many factors have driven the mergers and acquisitions of related pharmaceutical production, medical services and biotechnology companies. As China's aging society and the public's demand for medical and medical care are increasing, the price of medicines will increase. When released next year, it is foreseeable that the wave of mergers and acquisitions in the integrated pharmaceutical industry will be even higher.
According to the medical health research report, as of mid-November of this year, there were 343 domestic medical industry mergers and acquisitions in 2014, with a total amount of US$13.029 billion announced, and 119 M&A cases have been completed. The cumulative M&A volume has reached US$7.214 billion. These M&A activities are mainly extended and expanded through fixed growth and holding.
On November 26, the temporary shareholders meeting of Chutian Technology Co., Ltd. reviewed and approved the proposal to acquire Xinhuatong, which is to acquire 100% equity of Xinhuatong by issuing cash of shares. The transaction consideration is 550 million yuan. In this regard, Chu Tian Technology Chairman Tang Yue said, "We are committed to making the company one of the leading companies in the global medical equipment industry around 2025, when the company's global sales will reach 20 billion."
As of the middle of this year, Fosun Pharma Holdings has owned more than 2,000 approved beds for Jimin Hospital, Guangji Hospital, Zhongwu Hospital and Chancheng Hospital, and has basically formed high-end medical, second- and third-tier city specialists and general hospitals in coastal developed cities. The strategic layout of the combined medical services business. Fosun also participated in the US-China mutual benefit privatization project and cooperated to promote the domestic development of the latter's high-end medical service brand “Hejia†hospital. As of the middle of this year, it has achieved revenue of US$105 million.
In addition, many listed companies in the medical and health industry have actively participated in the tide of mergers and acquisitions through cooperation with private equity institutions and the establishment of M&A funds. Companies such as Aier Ophthalmology, Wuhan Jianmin and Jingxin Pharmaceutical are involved in the establishment of M&A funds. The scale is 200 million to 1 billion yuan, and the main investment direction of M&A funds is around the industrial chain and development strategy of listed companies. There is no shortage of attention in the field of traditional Chinese medicine, such as Paradise Silicon Valley, which was established by Jingxin Pharmaceutical. The main investment direction is the Chinese medicine and bio-pharmaceutical fields. Jianmin Zhongrong, established by Wuhan Jianmin, focuses on proprietary Chinese medicines, chemical medicines and bio-pharmaceuticals.
This year, listed pharmaceutical companies merged upstream and downstream, and horizontal mergers were significantly intensified. In the future, the M&A competition in the medical and medical industry will definitely become more intense. Now there is such a trend.
Monkeypox is a viral zoonosis (a virus transmitted tothose seen in the past in smallpox patients, typically-presents clinically with fever, rash and swollen lymphnodes and may lead to a range of medical complications.It is caused by the monkeypox virus which belongs totheorthopoxvirus genus of the Poxviridae family.Thereare two clades of monkeypox virus:the West Africanclade and the Congo Basin (Central African) clade.Theoname monkeypoxoriginates from the initial discovery ofthe virus in monkeys in a Danish laboratory in 1958.Thefirst human case was identified in a child in the Demo-cratic Republic of the Congo in 1970.
Monkey Pox Test Kit,In vitro diagnostic tests,Rapid detection of monkeypox
Jiangsu iiLO Biotechnology Co., Ltd. , https://www.iilogene.com